Dr Louise Winteringham

Home  >  Dr Louise Winteringham

Dr Louise Winteringham

Translational Cancer Research Program

Dr Louise Winteringham

Translational Cancer Research Program

Profile

Louise Winteringham leads the Translational Cancer Research Program at the Perkins. Shas an extensive background in immunology and haematology focusing on the molecular and cellular biology of cancer, in particular haematological cancers.

She completed her MSc in the Department of Clinical Immunology at Royal Perth Hospital investigating the impact of non-coding regions within the Major Histocompatibility Complex. Following three years working at St Bartholomew's Hospital in London, Louise was awarded the Richard Walter Gibbon Fellowship from the Faculty of Medicine, Dentistry and Health Sciences at UWA to undertake her PhD so she returned to Perth where she joined the Leukemia Laboratory at WAIMR, headed by Professor Peter Klinken. Louise continued her work in cancer research focusing on the biochemical and cellular mechanisms that drive oncogenesis. She has identified several novel genes associated with the development and progression of cancer. In 2017 she initiated the Translational Cancer Research Program at The Perkins, developing collaborations with pathologists and surgeons to provide a co-ordinated approach to quickly move laboratory discoveries into cancer treatments. As part of this program, she has established pre-clinical models able to accurately evaluate new cancer treatments that modulate our own immune systems to fight cancer. These models are also being used to develop precision oncology medicine in combination with several omics technologies.

Selected Publications

1. Arner E. et al. (including Winteringham LN). Transcribed enhancers lead waves of coordinated transcription in transitioning mammalian cells. Science (2015). [NCBI PubMed Entry]

2. Forrest A.R.R. et al. (including Winteringham LN) A promoter level mammalian expression atlas. Nature (2014) http://dx.doi.org/ 10.1038/nature13182.[NCBI PubMed Entry]

3. Endersby R, Majewski IJ, Winteringham LN, Beaumont JG, Samuels AL, Scaife R, Lim E, Crossley M, Klinken SP, Lalonde J. 2008. Hls5 regulates erythroid differentiation by modulating GATA-1 activity. Blood 111:1946-50. [NCBI PubMed Entry]

4. Winteringham LN, Endersby R, Kobelke S, McCulloch RK, Williams JH, Stillitano J, Cornwall SM, Ingley E, Klinken SP. 2006. Myeloid leukemia factor 1 associates with a novel heterogeneous nuclear ribonucleoprotein U-like molecule. The Journal of Biological Chemistry 281(50):38791-800. [NCBI PubMed Entry]

5. Winteringham LN, Kobelke S, Williams JH, Ingley E, Klinken SP. 2004. Myeloid Leukemia Factor 1 inhibits erythropoietin-induced differentiation, cell cycle exit and p27Kip1 accumulation. Oncogene 23(29):5105-9. [NCBI PubMed Entry]

6. Lim R, Winteringham LN, Williams JH, McCulloch RK, Ingley E, Tiao JY, Lalonde JP, Tsai S, Tilbrook PA, Sun Y, Wu X, Morris SW, Klinken SP. 2002. MADM, a novel adaptor protein that mediates phosphorylation of the 14-3-3 binding site of myeloid leukemia factor 1. The Journal of Biological Chemistry 277(43):40997-1008. [NCBI PubMed Entry]

7. Williams JH, Daly LN, Ingley E, Beaumont JG, Tilbrook PA, Lalonde JP, Stillitano JP, Klinken SP. 1999. HLS7, a hemopoietic lineage switch gene homologous to the leukemia-inducing gene MLF1. The EMBO Journal 18(20):5559-66. [NCBI PubMed Entry]